Startup profile · funding coverage
Orchestra Bio funding, valuation and investors
Agentic R&D operations platform unifying scientific, financial, and operational planning for biotechs.
Keep track of Orchestra Bio
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series A
$20M · 2025
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$20M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series a · San Francisco, California, USA
Investors in latest funding
Other: Andreessen Horowitz , 8VC , Insight Partners
Overview
Orchestra (orchestra.bio) is enterprise software for biotechnology R&D operations — not a therapeutics company. The platform unifies scientific roadmaps, budgets, hiring plans, and experiment tracking into one system of record with AI-assisted decision support. Founded by CEO Ashoka Rajendra and CTO Andy Xu, Orchestra raised $20M from Andreessen Horowitz, 8VC, Insight Partners, Definition, and Haystack per its 2025 blog. Customers use it to manage drug development programs across neurodegeneration, cancer, and metabolic disease. Do not confuse with publicly traded Orchestra BioMed (orchestrabiomed.com), a medical-device company.
Why Orchestra Bio is interesting
Not a drug company — Orchestra sells the “OS for science” to biotechs running complex program graphs, with $20M from a16z, 8VC, and Insight after pilots with neurodegeneration and oncology developers.
Product & use cases
Orchestra is an agentic operations platform for life-sciences R&D: unified planning across experiments, CRO management, financial modeling, and leadership dashboards. It aims to replace fragmented spreadsheets and point tools with one intelligent environment for bench-to-boardroom alignment.
- Centralizing R&D roadmaps and budget scenarios for clinical-stage biotechs
- Managing CRO relationships and experiment dependencies with agent-assisted workflows
- Giving executives a single source of truth for program burn and milestone risk
- Replacing ad hoc planning as biotech headcount and program complexity grow
Key facts
- Series A (2025): $20M from a16z, 8VC, Insight Partners, Definition, Haystack — Orchestra blog
- Product built with dozens of biotech design partners before GA
- Customers manage programs in neurodegeneration, cancer, metabolic disease — company blog
- Distinct from Orchestra BioMed (OBIO), a public medical-device company
- Co-investors not in VCT directory: Definition, Haystack
Funding history (newest first)
Investors in our directory
Funds linked from Orchestra Bio's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: Built with dozens of biotech design partners focusing on the operational layer — not ELN/LIMS science data alone. Founding team combines enterprise software and biotech operator experience.
Biotech ops software sits between scientific platforms (Benchling, Dotmatics) and generic ERP/FP&A. Orchestra bets R&D-specific intelligence — experiment graphs, CRO agents, scenario planning — wins as companies scale past seed stage. Crowded if incumbents add planning modules; win condition is becoming system-of-record for program operations.
-
Benchling adjacent
Dominant R&D cloud for scientific data and workflows; Orchestra targets financial/operational planning Benchling does not fully cover.
-
Planful / Anaplan adjacent
General enterprise FP&A; lack life-sciences R&D program semantics out of the box.
-
Spreadsheets + Notion incumbent
Default at early biotechs; break down as program graphs and burn complexity grow.
Notable stories
- CEO Ashoka Rajendra’s team spent years moving biotech workflows from paper to cloud before founding Orchestra, citing programs derailed by fragmented planning rather than bad science — Orchestra blog (2025).
- The company brands itself as building ‘agents for R&D’ at the intersection of biotech operations and enterprise AI — not a wet-lab therapeutics play.
Industries
Related funding articles
Venture Capital Tracker pieces that cover Orchestra Bio's financing or category context.
FAQs about Orchestra Bio
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.